iScience, Volume 24

## Supplemental information

## High resistance to *Toxoplasma gondii* infection

## in inducible nitric oxide synthase knockout rats

Zhen-Jie Wang, Shao-Meng Yu, Jiang-Mei Gao, Peng Zhang, Geoff Hide, Masahiro Yamamoto, De-Hua Lai, and Zhao-Rong Lun



**Figure S1. Measurement of IFN-***γ* **content in rat sera, Related to Figure 1.** (**A-C**) IFN-*γ* content was measured after being infected with the *T. gondii* RH/GFP (**A**), PLK/RED (**B**) and Tgctsd1 (**C**) strains. Rats were i.p. infected with  $10^7$  *T. gondii* tachyzoites and tail blood was collected at 3, 6 and 9 dpi; control groups were i.p. injected with equal volumes of PBS, n = 3. All data are presented as mean ± SD and are representative of three independent experiments. \*, *p* < 0.05; \*\*, *p* < 0.01; \*\*\*, *p* < 0.001; ns: no significant difference.



Figure S2. NO production in the supernatants of SD rat PMs preparations, Related to Figure 2. Supernatants were obtained at 24 hpi with *T. gondii* RH/GFP strain. MOI = 2, in 24-well plates,  $5 \times 10^5$  cells per well. All data are presented as mean ± SD and are representative of three independent experiments. n = 3; \*, *p* <0.5; \*\*, *p* <0.01; \*\*\*, *p* <0.001; \*\*\*\*\*, *p* < 0.0001; ns, no significant difference. LPS, Lipopolysaccharide; IFN-γ, interferon-gamma; SNP, sodium nitroprusside.



Figure S3. Images and quantification of *T. gondii* infection of rat NMFCs, rat PMs and BMDMs with the PLK/RED strain, Related to Figure 2. (A) *T. gondii* PLK/RED strain tachyzoites in SD rat NMFCs at 48 hpi. (B and C) The mean parasite load in *iNOS<sup>-/-</sup>*-SD (B) and WT-SD (C) rat NMFCs. (D) *T. gondii* PLK/RED tachyzoites in SD rat PMs at 48 hpi. (E and F) The mean parasite load in *iNOS<sup>-/-</sup>*-SD (E) and WT-SD (F) rat PMs (MOI = 2, cells were transferred into a 24-well plate,  $5 \times 10^5$  per well, n = 3. (G) BMDM cells at 24 hpi. (H) The mean parasite load in SD rat BMDMs. Scale bar, 50 µm. MOI = 2, cells were transferred into 24-well plates,  $5 \times 10^5$  per well. All data are presented as mean ± SD and are representative of three independent experiments, in triplicate, n = 3. \*\*, *p* < 0.01; \*\*\*, *p* < 0.001.



Figure S4. Changes in infection ratio of rat PMs with *T. gondii* after inhibition of caspase 1 or caspase 3, Related to Figure 4. The changes in infection ratio of *T. gondii* RH/GFP strain were counted at 24 hpi, cells and expressed as a fold change. Cells were transferred in 24-well plates with  $5 \times 10^5$  parasites per well; Rat PMs were pre-treated for 2h ahead of a 1h *T. gondii* invasion incubation and this was continued for the following 24h with the addition of inhibitors of caspase 1 (VX765 at 50 µM) or caspase 3 (MCC950 at 10 µM); MOI = 2. All data are presented as mean ± SD and are representative of three independent experiments, four replicates, n = 3; \*\*\*\*\*, *p*<0.0001; ns, no significant difference.



Figure S5. The infection ratio and ROS abundance in rat PMs infected with  $\Delta gra43$  *T*. *gondii*, Related to Figure 2 and Figure 4. (A-C) The infection ratio in WT-SD (A), *iNOS*<sup>-/-</sup>-SD (B) and LEW (C) rat PMs infected with *T. gondii* RH- $\Delta gra43$  or RH srain. (D and E) The relative cellular ROS content in PMs after infection with *T. gondii* RH- $\Delta gra43$  or RH strain at 1 hpi (D) and 3 hpi (E), following 30 min incubation with DCFH-DA. Cells were transferred in 24 well-plates, seeded at 5×10<sup>5</sup> per well, MOI = 2. All data are presented as mean ± SD and are representative of three independent experiments, n = 3. \*\*, *p* < 0.01; \*\*\*, *p* < 0.001; ns, no significant difference.



Figure S6. The infection ratio of SD rat PMs infected with *T. gondii* RH- $\Delta$ *rop18*, Related to Figure 2. Rat PMs were infected with *T. gondii* RH- $\Delta$ *rop18* or RH strain at 24 hpi; adherent cells were established in a 24 well plate, 5×10<sup>5</sup> per well, MOI = 2. All data are presented as mean ± SD and are representative of three independent experiments, n = 3. \*\*, p < 0.01; \*\*\*, p < 0.001; ns, no significant difference.



**Figure S7. Summary of the cell pyroptosis pathway induced by** *T. gondii* infection in *iNOS<sup>-/-</sup>SD* rat PMs, Related to Figure 4. *T. gondii* invades and forms a parasitophorous vacuole. Rat iNOS is induced to produce NO to provide self-defense. If this level of defense is missing, such as in the knockout rat, a novel alternative method comes into play. With the secretion of dense granule proteins (GRAs) from *T. gondii* and the lack of iNOS, the rat mitochondrion is over-activated and generates a reactive oxygen species (ROS) burst with the depletion of SOD2. The ROS burst may kill *T. gondii* directly, but more importantly, it induces pyroptosis. Pyroptosis then leads to the host cell disruption, together with destruction of the parasitophorous vacuole and this significantly limits the growth of the parasite.



**Figure S8.** Schematic diagram of the CRISPR/CAS9 strategy and diagnostic PCRs for identifying the *T. gondii* Gra43 knockout, Related to STAR Methods. (A) Schematic diagram showing the inactivation of GRA43 by inserting pyrimethamine-resistant DHFR (DHFR\*). Transfection of the sgGRA43 together with an amplicon containing a DHFR\*-expressing cassette flanked by homology regions to GRA43 was used to generate gene disruptions by insertion. The purple bar in the GRA43 gene represents the region targeted by the sgRNA. (B) Diagnostic PCRs of the *T. gondii* RH strain and RH-Δ*gra43* strain. The PCR1, PCR2 and PCR3 were performed to confirm the knock-out of *GRA43* in the *T. gondii* RH strain.

Table S1. Transcript fold change of TRAF6 and MyD88 in <i>iNOS<sup>-/-</sup>-SD</i> versus WT-SD rat.
Related to Figure 4.

Gene ID	Gene		Fold change in e	expression (P)	
	name	<i>iNOS<sup>-/-</sup>T. g</i> /WT <i>T. g</i>	<i>iNOS<sup>-/-</sup>T. g</i> /WTPBS	WT <sub>T. g</sub> /WT <sub>PBS</sub>	<i>iNOS<sup>-/-</sup>pbs/WTpbs</i>
ENSRNOG0	TDAEG	2.460867906	7.99512761	3.24449304	20
0000004639	I KAFO	(3.01E-07)	(3.18E-22)	(3.53E-05)	115
ENSRNOG0		3.026277582	13.4817743	4.4394018	20
0000013634	IVIYDOO	(2.70E-10)	(5.20E-33)	(3.53E-05)	115

RPKM, Reads Per Kilobase per Million mapped reads; ns, no significant difference; P, p value;

iNOS<sup>-/-</sup>T. g and WTT. g, T. gondii-inoculated iNOS<sup>-/-</sup>-SD and WT-SD rats, respectively; iNOS<sup>-/-</sup>PBS

and WT<sub>PBS</sub>, PBS-inoculated *iNOS*<sup>-/-</sup>-SD and WT-SD rats, respectively, n≥3.

Name	Sequence	Description	
gRNA-CRISPR-F	GAATCTCACCCGGCCATATTGTTTTA GAGCTAGAAATAGC	GRA43 specific CRISPR plasmid construction	
gRNA-CRISPR-R	AACTTGACATCCCCATTTAC		
GACCATGATTACGCCAAGCTTAT AATGCGTGACTTCAGC		G Amplification of the 5'	
5-GRA43R	ATTTACAGCCTGGCTTGGTGGTGGTT ATATGAGTCTC	homology arm of GRA43	
GRA43-DHFRF	CACCAAGCCAGGCTGTAAATCCCGTG AGTC	CGTG Amplification of the DHFR CGGT <sup>from pUPRT::DHFR-D</sup>	
GRA43-DHFRR	CGATTGTAGTCGATTCCGTCAGCGGT CTGTC		
3-GRA43F	GACGGAATCGACTACAATCGCCAGCT TGAAAC	۲ Amplification of the 3' <sub>A</sub> homology arm of GRA43	
3-GRA43R	GGTACCCGGGGATCCTCTAGATCGTA CTGTCGCCGTATCTTTTG		
GRA-P1F	TCAGCACGAATCATACCTCAGA	PCR1 for verifying the Δ <i>gra43</i> mutation	
GRA-P1R	AGACAAGACGCAGACGCATA		
GRA-P2F	ACTTGTTGTGCCAGTTCTACG	PCR2 for verifying the Δ <i>gra43</i> mutation	
GRA-P2R	CTGCGGTTAATCGGTCCTTC		
GRA-inF	GTTGGTGGTAGGCGTGGAA	PCR3 for verifying the Δ <i>gra43</i> mutation	
GRA-inR	TCTTGTGTTGACTGGGCATTG		

Methods.